Menu
Not yet recruiting NCT07291375

Role of Amlodipine in Reduction of CIN

Early Phase I Interventional Contrast-induced Nephropathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Calcium channel blocker, Hydration.
Who it may be relevant to
Registry conditions: Contrast-induced Nephropathy. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Effect of Low Dose Oral Amlodipine in Renal Protection From Contrast Induced Nephropathy in Diabetic Patients in Intensive Care Unit

Overview

The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit

Interventions

  • Drug Calcium channel blocker
    amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour
  • Other Hydration
    before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml/h of normal saline

Primary outcome measures

  • measuring serum creatinine level [Time frame: baseline]

Eligibility criteria

Inclusion criteria

  • adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3

Exclusion criteria

  • patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07291375 · Amlodipine role in CIN

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗